Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1368 articles with Gilead Sciences, Inc.
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead’s senior leadership team.
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.
Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
New Option for Adult Patients in Europe as Axicabtagene Ciloleucel Becomes the First CAR T to Receive European Approval for Two Types of Aggressive Non-Hodgkin Lymphoma
Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling Hi...
8/23/2018Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and n...
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
8/20/2018This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
Foster City, Calif.-based Gilead Sciences reorganized some of its executive leadership team after it was announced that Chief Medical Officer Andrew Cheng is leaving the company to pursue other opportunities.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients.
In January 2016, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding slightly different formulations of tenofovir, a key HIV/AIDS drug found in Gilead’s all-in-one Fixed Dose Combination HIV/AIDS treatments.
China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection
Genvoya is the First TAF-Based Regimen Approved in China for Adults and Adolescents with HIV
Legal actions filed by two patients with HIV from Louisiana targets Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).
Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer.